ibrexafungerp: Clinical Trials

6 completed, 1 terminated. 7 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	7	Completed 6, Terminated 1

Follow ibrexafungerp: new trials by email Literature Review of ibrexafungerp trials Research Report on ibrexafungerp

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole SCY-078, Fluconazole, Echinocandin - Candidiasis, Invasive, Candidemia	Phase 3	Terminated	Scynexis, Inc.	68	2022-08-03	2026-08-10
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis Ibrexafungerp - Vulvovaginal Candidiasis	Phase 3	Completed	Scynexis, Inc.	150	2022-05-01	2024-07-10
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet - Recurrent Vulvovaginal Candidiasis	Phase 3	Completed	Scynexis, Inc.	440	2019-10-21	2023-06-18
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Ibrexafungerp, Placebo - Candida Vulvovaginitis	Phase 3	Completed	Scynexis, Inc.	455	2019-06-07	2021-09-08
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303) Ibrexafungerp, Placebo - Candida Vulvovaginitis	Phase 3	Completed	Scynexis, Inc.	376	2019-01-04	2021-09-08
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) SCY-078 - Candidiasis, Invasive, Candidemia	Phase 3	Completed	Scynexis, Inc.	30	2017-11-15	2024-07-03
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Ibrexafungerp - Invasive Candidiasis, Mucocutaneous Candidiasis	Phase 3	Completed	Scynexis, Inc.	233	2017-04-01	2024-11-20

Conditions studied

Candidiasis, Vulvovaginal (5)  ·  Candidiasis, Invasive (3)  ·  Candidemia (2)  ·  Aspergillosis, Allergic Bronchopulmonary (1)  ·  Blastomycosis (1)  ·  Candidiasis, Chronic Mucocutaneous (1)  ·  Coccidioidomycosis (1)  ·  Histoplasmosis (1)  ·  Invasive Pulmonary Aspergillosis (1)  ·  Torulopsis (1)  ·  Vaginitis (1)

Sponsors

Scynexis, Inc. (7)

Countries

United States (7)  ·  South Africa (3)  ·  Bulgaria (2)  ·  Germany (2)  ·  Pakistan (2)  ·  Spain (2)  ·  Austria (1)  ·  Belgium (1)  ·  Canada (1)  ·  China (1)  ·  France (1)  ·  Greece (1)  ·  India (1)  ·  Israel (1)  ·  Italy (1)

Top investigators

David Angulo, MD (3)  ·  Lori Tierney (1)  ·  Nkechi Azie, MD (1)

Results publications

PMID 36255448, PMID 40970688

NIH funding

2017 (1)